

In collaboration with:

Corneal Epithelial Regeneration: From Limbal Stem Cell Transplant to Descemet's Membrane Transplant - KKESH Experience

Muhammad A Ahad, MRCOphth, FRCS, PhD

Senior Academic Consultant & Head of Anterior Segment Division

King Khaled Eve Specialist Hospital, Rivadh







No financial interests related to this talk





Causes of Poor epithelial regeneration cialist Hospital

- Limbal stem cell deficiency
- Neurotrophic
 - Diabetes/Viral/Dry eyes/ Nerve damage/ PKP
- Defective epithelial adhesion
 - RCEs/dystrophies /drops/ Bullous keratopathy /Vitamin A deficiency
- Inflammation
 - Microbial/ viral keratitis
- Mechanical/Physical
 - Entropion/ PKP



Causes of LSCD

- Alkali-induced chemical injury
- Congenital/ Aniridia
- OCP/SJS
- multiple surgeries
- Preservatives in drops*
- Vernal keratoconjunctivitis
- Infections

EOS 2025 EGYPTIAN OPHTHALMOLOGICAL SOCIETY



مستشيفي الملك خالد لتخصصى للعيون



- <u>Control the inflammation</u>
- Fix the lids and Fornices

LSCD Surgical Options

- Conjunctival Limbal Autograft 1989
- Kerato-limbal Allograft 1997
- CLET: 2004
- SLET: 2012
- Holoclar: 2015 (commercial)
- CALEC : 2019 (xeno free)/ USA











26 years old with 12 months history of chemical injury VA 20/400





1 week Post Op

EOS 2025 EGYPTIAN OPHTHALMOLOGICAL SOCIETY 2m post Op VA 20/50



مستشفى الملك خالد التخصصي للعيون King Khaled Eye Specialist Hospital



32 with LSCD due to VKC (h/o shield ulcers as well)









What if there is Partial LSCD





- Superficial Keratectomy with AMT
- Sequential Sectoral Conjunctival Epitheliectomy (SSCE)

• Decellularized Descemet's Membrane transplant

BrightMEM[®] : Decellularized Descemet's Membrane

- Decellularized Descemet's membrane (DM)
- Retains **native DM ultrastructure** free of cellular antigens.
 - (no immunogenic response)
- Acts as a scaffold for limbal epithelial cell migration and proliferation.

Bright Star Therapeutics







Theory

- When LSC leaves the niche they lose their stem cell ability and just divide into mature epithelial cells
- Anterior side of Descemet's membrane, contains proteins
- Same proteins that are found in the limbal niche but not found in the central cornea so this DM can act like a limbal niche, ideally keeping stem cells alive long term in the center.

Case Reports Corries, 2025 Jan 1;44(1):108-112. doi: 10.1097/ICO.00000000003565. Epub 2024 May 3.

Decellularized Descemet Membrane Anterior Keratoplasty With Allogeneic Simple Limbal Epithelial Transplantation for Partial Limbal Stem Cell Deficiency Following Partial Keratolimbal Allograft Failure

Albert Y Cheung 🎘 Z, Cameron B Beinisch 🖾, Joshua H Hou 💐

Affiliations + expand PMID: 38713471 DOI: 10.1097/ICO.00000000000565

Abstract

Purpose: The purpose of this study was to describe the use of Descennet membrane anterior keratoplasty (DMAK) with modified allogeneic simple limbal epithelial transplantation to treat a case of partial limbal stem cell deliciency (LSCD) following keratolimbal allograft failure.

Methods: Case report.

Results: A 21-year-old woman with autoimmune polyglandular syndrome-related LSCD presented with pain and decreased vision. There was partial failure and recurrence of LSCD after a severe/acute keratolimbal allograft rejection that led to persistent epithelial defects refractory to conservative therapy. This was treated with a superficial keratectomy and placement of a DMAK. A modified allogeneic simple limbal epithelial transplantation was performed with an overlying anniotic membrane and temporary tarsorrhaphy. There was epithelialization of the corneal surface by 3 to 4 weeks with an improved ocular surface. Despite partial recurrence of late staining, the cornea has remained epithelized, vision has improved, and the patient has remained pain-free more than 1.5 years following the procedure.

Conclusions: DMAK may be a long-term substrate to help improve and maintain epithelization of the comea up to 1.5 years. DMAK may be a viable alternative to using amniotic membrane as a scallold in allogeneic simple limbal epithelial transplantation for treatment of partial LSCD. While late epithelial staining recurred in our patient, DMAK appears to prevent recurrent epithelial defects and reduce ocular surface pain, conveying an improvement in quality of file in patients at high risk of rejection/

Cornea, 2025 May 2, doi: 10.1097/ICO.000000000003892. Online ahead of print.

Use of Decellularized Descemet Membrane Anterior Keratoplasty to Facilitate Epithelialization of Pediatric Penetrating Keratoplasty for Total Sclerocornea

Radwa Elsharawi ³⁴, Daniel Lee ³⁰, Abhiniti Mittal ³⁵, Winston D Chamberlain ³⁵, Joseph Jauber ³⁰, Jravis K Redd ³¹

Affiliations + expand PMID: 40315363 DOI: 10.1097/ICO.00000000003892

Abstract

Purpose: To report the first known use of combined decellularized Descennet membrane anterior keratoplasty with penetrating keratoplasty (PKP) in a pediatric patient.

Methods: A 2-month-old boy with bilateral sclerocomea underwent bilateral sequential PKP. In the felt eye, PKP performed at 2 months of age was complicated by a persistent epithelial defect postoperatively with a 1 month delay in epithelialization. As a result, the patient underwent PKP with a combined decellularized Descennet membrane comeal allograft implantation in the right eye at 3 months of age to enhance early postoperative healing. This was performed by creating a central 3-mm superficial keratectomy before placing Descennet membrane allograft onto the full-thickness graft.

Results: Compared to the 1-month delay in epithelialization alter PKP in the left eye, the right eye, which underwent combined PKP and decellularized Descennet membrane corneal allograft, was fully epithelialized by the first postoperative week. The grafts remain clear and intact at 12 months of age. The patient exhibited significant improvement in visual behavior.

Conclusions: This case highlights the successful use of decellularized Descennet membrane anterior keratoplasty in preventing a persistent epithelial delect in the early postoperative period for a pediatric patient with sclerocomea. This may be a viable option for similar pediatric cases with delayed epithelial healing while promoting graft survival and minimizing the need for additional surgical interventions.





























Insulin Eye drops

- Promotes Epithelial migration
- Indicated for PED due to
 - NK
 - LSCD
- Multiple Concentration

EOS 2025 EGYPTIAN OPHTHALMOLOGICAL SOCIETY

Review > 1 Curr Ophthalmol. 2024 Oct 16;36(1):9-22. doi: 10.4103/joco.joco. 32-24. eCollection 2024 Jan-Mar.

Topical Insulin for Neurotrophic-Related Epithelial Defects: Where do We Stand? A Systematic Review

Colette Wouters $^{[0]}$, Isabelle Saelens $^{[1]}$, Heleen Delbeke $^{[1]}$

Alfilations + expand PMID: 89553318 - PMCD: PMC11567610 - DOI: 10.4103/joco.joco. 32-24

Abstract

Purpose: To review the existing literature to evaluate the utility of insulin eye drops as a treatment for neurotrophic related epithelial defects.

Methods: A comprehensive literature search of Medline, Embase, and Web of Science and additional manual searches were conducted using relevant keywords. All articles published from January 2005 to January 2024 were examined. Studies on the use of topical insulin drops in neurotrophic epithelial defects were included.

Results: A total of 16 articles were found relevant to be discussed in the review. All included patients had neurotrophic related epithelial defects ranging from 3.8 mm² to 144 mm². After treatment with topical insulin, most of the epithelial defects showed a complete epithelialization. Various concentrations and types of insulin were used. The studies also varied in the type of vehicle used in the preparation of insulin drops. Two randomized controlled trials demonstrated that topical insulin drops were more effective than conventional treatment with artificial tears or autologous serum. All included studies, except for two, reported the absence of local or systemic side effects.

Conclusions: topical insulin is a premising and effective (adjuvant) treatment for neurotrophic keratopathy. It facilitates the healing of neurotrophic epithelial defects and offers many advantages over the current treatment options; insulin is widely available and it is relatively inexpensive. Topical insulin drops do not affect systemic blood glucose levels and are well tolerated. However, further investigation is needed.

Eye drops Preparations	Insulin	Insulin
Concentration	25 IU/ml	1 IU/ml
Source:	Injection	Injection
Solvent base	Normal Saline	Propylene Glycol
Preservatives?	No	No
Expiry	4 days	30 days
Shelf life once prepared	4 days	30 days
storage	Refrigerated	Refrigerated

Moreker MR, Insulin eye drops for neurotrophic keratitis. Indian J Ophthalmol. 2023 Jul;71(7):2911-2912. doi: 10.4103/IJO.IJO_872_23.

Bastion, M. L., "Topical insulin for healing of diabetic epithelial defects?: A retrospective review of corneal debridement during vitreoretinal surgery in Malaysian patients." Med J Malaysia 68.3 (2013): 209

Insulin drops

- Good Response post Keratoplasty (LKP/PKP)
- Modest response in simple PED
- Modest response in established NK

10 R A N D U N Kine Khaled Eve 09 July 2024 G Specialist Hospita 02 Muhamam 1446 H Toc Principal Investigator Location: Medical Staff Rinnie From: MD. IRB Chair Location: Research Department RP 24058-P The Effects of Insulin Drops Application on Corneal Epithelial Subject: Healing After Lamellar Keratoplasty- A Comparative Study Reference: RD/28001/RB/0407-24

ستشيفي الملك خالد لتخصصى للعيون

Good response post multiple surgeries (combination of NK/LSCD)



Better response in LSCD



EGYPTIAN OPHTHALMOLOGICAL SOCIETY







In Summary

- SLET appears very effective procedure in cases of total LSCD particularly due to chemical injury
- In cases of partial/less than total LSCD, BrightMEM has shown promising results
- Insulin eye drops can be used as an adjunct in promoting healing





THANK YOU

